Novartis AG has developed a new kidney disease field team to help market Fabhalta (iptacopan) for primary immunoglobulin A nephropathy (IgAN) while relying on its existing hematology infrastructure to market the drug for paroxysmal nocturnal hemoglobinuria (PNH), with an eye toward developing a large nephrology franchise in the coming years.
The US Food and Drug Administration granted accelerated approval to Fabhalta for reducing proteinuria in adults with IgAN and at risk of rapid disease progression on 7 August
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?